BioWorld - Sunday, December 14, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector

BioWorld Science, Endocrine/metabolic
BioWorld Science, Endocrine/metabolic RSS Feed RSS

Endocrine/metabolic

Hansoh discovers new GIPR, GCGR and GLP-1R agonists

Dec. 12, 2025
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described compounds acting as gastric inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonists reported to be useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD, NAFLD), diabetes and obesity.
Read More
Illustration of human body composed of molecules
Endocrine/metabolic

In vivo base editing corrects two major phenylketonuria variants in mice

Dec. 10, 2025
No Comments
Phenylketonuria (PKU) is an autosomal recessive disorder that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems and mental disorders. This metabolic disease is caused by mutations in the phenylalanine hydroxylase (PAH) gene, resulting in patients’ inability to convert phenylalanine.
Read More
Lab glassware and antibodies art concept
Endocrine/metabolic

Neurimmune inks deal to advance NI-009 for AL amyloidosis

Dec. 5, 2025
No Comments
Neurimmune AG has expanded its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, Astrazeneca Rare Disease by entering into an exclusive global collaboration and license agreement to develop NI-009, a fibril depleter for light chain (AL) amyloidosis.
Read More
Endocrine/metabolic

Chinese scientists divulge new XOR inhibitors

Dec. 3, 2025
Apichope Bio Pharmaceutical Co. Ltd., Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have synthesized xanthine dehydrogenase/oxidase (XDH; XOR) inhibitors reported to be useful for the treatment of hyperuricemia, gout, arthritis and heart failure.
Read More
Endocrine/metabolic

Chinese researchers patent new URAT1 inhibitors

Dec. 2, 2025
Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have disclosed solute carrier family 22 member 12 (SLC22A12; URAT1) inhibitors reported to be useful for the treatment of hyperuricemia, nephropathy and gout.
Read More
Endocrine/metabolic

TSHR antagonists disclosed in Genescience patent

Dec. 1, 2025
Genescience Pharmaceuticals Co. Ltd. has divulged thyroid-stimulating hormone (thyrotropin) receptor (TSHR) antagonists reported to be useful for the treatment of hyperthyroidism, Grave’s disease and thyroid-associated ophthalmopathy (Grave’s ophthalmopathy).
Read More